Quiescence Preconditioned Human Multipotent Stromal Cells Adopt a Metabolic Profile Favorable for Enhanced Survival under Ischemia

Stem Cells

Volumn 35, Issue 1, 2017, Pages 181-196

  Moya, Adrien ^a   Larochette, Nathanaël ^a   Paquet, Joseph ^a   Deschepper, Mickael ^a   Bensidhoum, Morad ^a   Izzo, Valentina ^b,c,d,e   Kroemer, Guido ^{b,c,d,e,f,g,h}   Petite, Hervé ^a   Logeart Avramoglou, Delphine ^a  

^a Paris university   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autophagy; Cell metabolism; Cell survival; Human mesenchymal stromal cells; Ischemia; Quiescence

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; FRUCTOSE 1,6 BISPHOSPHATASE ISOZYME 2; FRUCTOSE BISPHOSPHATASE; GLUCOSE; LACTIC ACID; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; OXYGEN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOENOLPYRUVATE CARBOXYKINASE 1; PHOSPHOENOLPYRUVATE CARBOXYKINASE 2; PYRUVIC ACID; S6 KINASE; UNCLASSIFIED DRUG;

ACIDIFICATION; ADULT; APOPTOSIS; ARTICLE; AUTOPHAGY; BIOENERGY; BIOLUMINESCENCE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; BONE MARROW STROMA CELL; CELL HYPOXIA; CELL METABOLISM; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENERGY METABOLISM; G1 PHASE CELL CYCLE CHECKPOINT; GLUCONEOGENESIS; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIA; METABOLIC STRESS; MOUSE; MULTIPOTENT STEM CELL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RNA SYNTHESIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; UPREGULATION; CELL CULTURE; CELL CYCLE; CELL CYCLE CHECKPOINT; CYTOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; METABOLOME; PATHOLOGY; PHYSIOLOGICAL STRESS; REPERFUSION; SERUM-FREE MEDIUM;

ADENOSINE TRIPHOSPHATE; AUTOPHAGY; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; HUMANS; ISCHEMIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; METABOLOME; REPERFUSION; STRESS, PHYSIOLOGICAL;

EID: 84988418451     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2493     Document Type: Article

References (46)

1. Friedenstein AJ, Petrakova KV, Kurolesova AI et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968;6:230–247.
2. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007;213:341–347.
3. Giannoni P, Scaglione S, Daga A et al. Short-time survival and engraftment of bone marrow stromal cells in an ectopic model of bone regeneration. Tissue Eng Part A 2009;16:489–499.
4. Liu J, Barradas A, Fernandes H et al. In vitro and in vivo bioluminescent imaging of hypoxia in tissue-engineered grafts. Tissue Eng Part C Methods 2010;16:479–485.
5. Rodrigues M, Griffith LG, Wells A. Growth factor regulation of proliferation and survival of multipotential stromal cells. Stem Cell Res Ther 2010;1:32.
6. Wu KH, Mo XM, Han ZC et al. Stem cell engraftment and survival in the ischemic heart. Ann Thorac Surg 2011;92:1917–1925.
7. Becquart P, Cambon-Binder A, Monfoulet LE et al. Ischemia is the prime but not the only cause of human multipotent stromal cell death in tissue-engineered constructs in vivo. Tissue Eng Part A 2012;18:2084–2094.
8. Haider H, Ashraf M. Strategies to promote donor cell survival: Combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol 2008;45:554–566.
9. Patel ZS, Mikos AG. Angiogenesis with biomaterial-based drug- and cell-delivery systems. J Biomater Sci Polym Ed 2004;15:701–726.
10. Pedersen TO, Blois AL, Xing Z et al. Endothelial microvascular networks affect gene-expression profiles and osteogenic potential of tissue-engineered constructs. Stem Cell ResTher 2013;4:52.
11. Wallner C, Schira J, Wagner JM et al. Application of VEGFA and FGF-9 enhances angiogenesis, osteogenesis and bone remodeling in Type 2 diabetic long bone regeneration. PloS One 2015;10:e0118823.
12. Niagara MI, Haider H, Jiang S et al. Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res 2007;100:545–555.
13. Wisel S, Khan M, Kuppusamy ML et al. Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression. J Pharmacol Exp Ther 2009;329:543–550.
14. Deng J, Han Y, Yan C et al. Overexpressing cellular repressor of E1A-stimulated genes protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis by activation of PI3K/Akt. Apoptosis 2010;15:463–473.
15. Fan VH, Tamama K, Au A et al. Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. Stem Cells 2007;25:1241–1251.
16. Rodrigues M, Yates CC, Nuschke A et al. The matrikine tenascin-C protects multipotential stromal cells/mesenchymal stem cells from death cytokines such as FasL. Tissue Eng Part A 2013;19:1972–1983.
17. Deschepper M, Manassero M, Oudina K et al. Pro-angiogenic and pro-survival functions of glucose in human mesenchymal stem cells upon transplantation. Stem Cells 2013;31:526–535.
18. Deschepper M, Oudina K, David B et al. Survival and function of mesenchymal stem cells (MSCs) depend on glucose to overcome exposure to long-term, severe and continuous hypoxia. J Cell Mol Med 2011;15:1505–1514.
19. Cheung TH, Rando TA. Molecular regulation of stem cell quiescence. Nat Rev Mol Cell Biol 2013;14:329–340.
20. Friedenstein AJ, Chailakhyan RK Gerasimov UV. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell and Tissue Kinetics 1987;20:263–272.
21. Logeart-Avramoglou D, Oudina K, Bourguignon M et al. In vitro and in vivo bioluminescent quantification of viable stem cells in engineered constructs. Tissue Eng Part C Methods 2010;16:447–458.
22. Degat MC, Dubreucq G, Meunier A et al. Enhancement of the biological activity of BMP-2 by synthetic dextran derivatives. J Biomed Mater Res a 2009;88:174–183.
23. LoPiccolo J, Blumenthal GM, Bernstein WB et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008;11:32–50.
24. Gharibi B, Farzadi S, Ghuman M et al. Inhibition of Akt/mTOR attenuates age-related changes in mesenchymal stem cells. Stem Cells 2014;32:2256–2266.
25. Qian W, Van Houten B. Alterations in bioenergetics due to changes in mitochondrial DNA copy number. Methods 2010;51:452–457.
26. Coller HA, Sang L, Roberts JM. A new description of cellular quiescence. PLoS Biol 2006;4:e83.
27. Winer JP, Janmey PA, McCormick ME et al. Bone marrow-derived human mesenchymal stem cells become quiescent on soft substrates but remain responsive to chemical or mechanical stimuli. Tissue Eng Part A 2009;15:147–154.
28. Zhu W, Chen J, Cong X et al. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 2006;24:416–425.
29. Potier E, Ferreira E, Meunier A et al. Prolonged hypoxia concomitant with serum deprivation induces massive human mesenchymal stem cell death. Tissue Eng 2007;13:1325–1331.
30. Beegle J, Lakatos K, Kalomoiris S et al. Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo. Stem Cells 2015;33:1818–1828.
31. Manassero M, Paquet J, Deschepper M et al. Comparison of survival and osteogenic ability of human mesenchymal stem cells in orthotopic and ectopic sites in mice. Tissue Eng Part A 2016;22:534–544.
32. Stegen S, van Gastel N, Eelen G et al. HIF-1alpha promotes glutamine-mediated redox homeostasis and glycogen-dependent bioenergetics to support postimplantation bone cell survival. Cell Metab 2016;23:265–279.
33. Gray JV, Petsko GA, Johnston GC et al. “Sleeping beauty”: Quiescence in Saccharomyces cerevisiae. Microbiol Mol Biol Rev 2004;68:187–206.
34. Stuart JA, Brown MF. Energy, quiescence and the cellular basis of animal life spans. Comp Biochem Physiol Part A Mol Integr Physiol 2006;143:12–23.
35. Folmes CD, Dzeja PP, Nelson TJ et al. Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell 2012;11:596–606.
36. Latil M, Rocheteau P, Chatre L et al. Skeletal muscle stem cells adopt a dormant cell state post mortem and retain regenerative capacity. Nat Commun 2012;3:903.
37. Buttgereit F, Brand MD. A hierarchy of ATP-consuming processes in mammalian cells. Biochem J 1995;312: 163–167.
38. Boutilier RG. Mechanisms of cell survival in hypoxia and hypothermia. J Exp Biol 2001;204:3171–3181.
39. Ochocki JD, Simon MC. Nutrient-sensing pathways and metabolic regulation in stem cells. J Cell Biol 2013;203:23–33.
40. Valcourt JR, Lemons JM, Haley EM et al. Staying alive: Metabolic adaptations to quiescence. Cell Cycle 2012;11:1680–1696.
41. Galluzzi L, Morselli E, Vicencio JM et al. Life, death and burial: multifaceted impact of autophagy. Biochem Soc Trans 2008;36:786–790.
42. Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: Cell death or cell survival? Curr Opin Cell Biol 2010;22:177–180.
43. Ito K, Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. Nat Rev Mol Cell Biol 2014;15:243–256.
44. Buravkova LB, Andreeva ER, Gogvadze V et al. Mesenchymal stem cells and hypoxia: where are we? Mitochondrion 2014;19: 105–112.
45. Folmes CD, Nelson TJ, Martinez-Fernandez A et al. Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab 2011;14:264–271.
46. Leithner K, Hrzenjak A, Trotzmuller M et al. PCK2 activation mediates an adaptive response to glucose depletion in lung cancer. Oncogene 2015;34:1044–1050.